Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study-Reference-Cited by-同舟云学术

Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study

Published:2014-01 Issue:1 Volume:38 Page:57-64
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Neukirchen Judith,Lauseker Michael,Blum Sabine,Giagounidis Aristoteles,Lübbert Michael,Martino Samuela,Siragusa Sergio,Schlenk Richard F.,Platzbecker Uwe,Hofmann Wolf-Karsten,Götze Katharina,Palumbo Giuseppe A.,Magrin Silvana,Kündgen Andrea,Aul Carlo,Hildebrandt Barbara,Hasford Joerg,Kobbe Guido,Haas Rainer,Germing Ulrich

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference41 articles.

1. Proposals for the classification of the myelodysplastic syndromes;Bennett;Br J Haematol,1982

2. Myelodysplastic syndromes/neoplasms, overview;Brunning,2008

3. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes;Germing;Ann Hematol,2008

4. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

5. Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes;Germing;Leukemia,2005

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinico-hematological Profile and Cytogenetics in Myelodysplastic Syndrome - A Tertiary Care Experience;Research Journal of Pharmacy and Technology;2024-02-20

2. The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes;Blood;2023-12-28

3. Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms;Future Oncology;2023-09

4. Impact of IPSS-M implementation in real-life clinical practice;Frontiers in Oncology;2023-05-18

5. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents;Current Hematologic Malignancy Reports;2023-04-13